Dmitri Simberg
Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nanoparticles | 33 | 2025 | 484 | 8.870 |
Why?
| | Liposomes | 20 | 2025 | 231 | 4.390 |
Why?
| | Polyethylene Glycols | 15 | 2025 | 641 | 4.090 |
Why?
| | Complement Activation | 18 | 2025 | 415 | 4.090 |
Why?
| | Nanomedicine | 12 | 2025 | 46 | 3.960 |
Why?
| | Dextrans | 13 | 2024 | 85 | 3.740 |
Why?
| | Complement C3 | 10 | 2024 | 203 | 3.370 |
Why?
| | Drug Delivery Systems | 16 | 2025 | 363 | 2.940 |
Why?
| | Doxorubicin | 7 | 2025 | 360 | 2.820 |
Why?
| | Ferric Compounds | 7 | 2025 | 55 | 2.180 |
Why?
| | Complement System Proteins | 11 | 2024 | 333 | 2.140 |
Why?
| | Drug Carriers | 10 | 2024 | 127 | 2.130 |
Why?
| | Magnetite Nanoparticles | 9 | 2019 | 28 | 2.050 |
Why?
| | Microbubbles | 7 | 2017 | 49 | 1.890 |
Why?
| | Neoplastic Cells, Circulating | 4 | 2017 | 76 | 1.690 |
Why?
| | Mice, Inbred BALB C | 18 | 2025 | 1275 | 1.530 |
Why?
| | Leukocytes | 5 | 2023 | 309 | 1.490 |
Why?
| | Complement Inactivating Agents | 2 | 2025 | 66 | 1.480 |
Why?
| | Macrophages | 8 | 2023 | 1562 | 1.460 |
Why?
| | Lipids | 7 | 2025 | 690 | 1.400 |
Why?
| | Ferrosoferric Oxide | 4 | 2019 | 24 | 1.390 |
Why?
| | Receptors, Scavenger | 3 | 2016 | 23 | 1.230 |
Why?
| | Immunoglobulins | 3 | 2024 | 168 | 1.160 |
Why?
| | Mice | 37 | 2025 | 18109 | 1.150 |
Why?
| | Scavenger Receptors, Class A | 3 | 2019 | 12 | 1.130 |
Why?
| | Animals | 51 | 2025 | 37749 | 1.100 |
Why?
| | Immunoglobulin M | 3 | 2024 | 287 | 1.080 |
Why?
| | Opsonin Proteins | 2 | 2019 | 24 | 1.080 |
Why?
| | Cell Membrane | 4 | 2019 | 724 | 1.050 |
Why?
| | Cetuximab | 2 | 2018 | 105 | 1.040 |
Why?
| | Antibodies | 2 | 2019 | 411 | 1.020 |
Why?
| | Immunoglobulin G | 4 | 2025 | 900 | 1.020 |
Why?
| | Erythrocytes | 5 | 2019 | 707 | 0.960 |
Why?
| | Glioblastoma | 3 | 2025 | 348 | 0.940 |
Why?
| | Single-Domain Antibodies | 1 | 2025 | 15 | 0.920 |
Why?
| | Cell Separation | 2 | 2017 | 317 | 0.870 |
Why?
| | Lipoproteins | 1 | 2025 | 163 | 0.870 |
Why?
| | Antineoplastic Agents | 5 | 2019 | 2169 | 0.790 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2023 | 31 | 0.780 |
Why?
| | Receptors, Complement 3d | 1 | 2023 | 140 | 0.770 |
Why?
| | Contrast Media | 3 | 2017 | 470 | 0.760 |
Why?
| | Endothelium | 2 | 2022 | 127 | 0.750 |
Why?
| | Cell-Penetrating Peptides | 2 | 2025 | 22 | 0.750 |
Why?
| | Cell Line, Tumor | 14 | 2025 | 3495 | 0.740 |
Why?
| | Click Chemistry | 2 | 2019 | 50 | 0.730 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2024 | 855 | 0.720 |
Why?
| | Phosphatidylethanolamines | 5 | 2014 | 76 | 0.720 |
Why?
| | Quaternary Ammonium Compounds | 5 | 2006 | 51 | 0.700 |
Why?
| | Complement Pathway, Alternative | 3 | 2017 | 123 | 0.700 |
Why?
| | Fatty Acids, Monounsaturated | 5 | 2006 | 54 | 0.700 |
Why?
| | Neoplasms | 5 | 2024 | 2747 | 0.700 |
Why?
| | Surface Properties | 7 | 2018 | 414 | 0.700 |
Why?
| | Blood Proteins | 4 | 2019 | 250 | 0.690 |
Why?
| | Glioma | 2 | 2025 | 427 | 0.670 |
Why?
| | Saccharomyces cerevisiae | 1 | 2025 | 556 | 0.670 |
Why?
| | Fluorocarbons | 3 | 2013 | 134 | 0.640 |
Why?
| | Brain Neoplasms | 3 | 2025 | 1305 | 0.620 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 97 | 0.610 |
Why?
| | Perfusion | 1 | 2020 | 228 | 0.610 |
Why?
| | CD55 Antigens | 1 | 2019 | 29 | 0.610 |
Why?
| | Humans | 56 | 2025 | 141754 | 0.610 |
Why?
| | Cell-Derived Microparticles | 1 | 2020 | 75 | 0.600 |
Why?
| | Collagen Type II | 1 | 2019 | 55 | 0.600 |
Why?
| | Protein Corona | 1 | 2019 | 5 | 0.600 |
Why?
| | Cyclooctanes | 1 | 2018 | 5 | 0.600 |
Why?
| | Skin | 3 | 2020 | 765 | 0.590 |
Why?
| | Bone Marrow | 1 | 2020 | 302 | 0.580 |
Why?
| | Urinary Bladder | 2 | 2020 | 195 | 0.580 |
Why?
| | Lymphocytes | 2 | 2020 | 398 | 0.570 |
Why?
| | Transfection | 4 | 2005 | 943 | 0.550 |
Why?
| | Antigens, Neoplasm | 4 | 2014 | 322 | 0.540 |
Why?
| | Intravital Microscopy | 1 | 2017 | 24 | 0.540 |
Why?
| | Biological Transport | 5 | 2020 | 410 | 0.530 |
Why?
| | Monocytes | 1 | 2020 | 579 | 0.520 |
Why?
| | Skin Absorption | 1 | 2017 | 14 | 0.520 |
Why?
| | Protein Binding | 8 | 2019 | 2242 | 0.520 |
Why?
| | Phagocytes | 3 | 2023 | 103 | 0.520 |
Why?
| | Lipid Bilayers | 1 | 2018 | 106 | 0.520 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2017 | 131 | 0.510 |
Why?
| | Inflammation Mediators | 1 | 2019 | 519 | 0.500 |
Why?
| | Liver | 3 | 2023 | 1820 | 0.500 |
Why?
| | Coated Materials, Biocompatible | 1 | 2016 | 65 | 0.500 |
Why?
| | Mucous Membrane | 1 | 2017 | 127 | 0.490 |
Why?
| | Spectrometry, Fluorescence | 1 | 2017 | 167 | 0.490 |
Why?
| | Particle Size | 5 | 2018 | 404 | 0.490 |
Why?
| | Superoxide Dismutase | 1 | 2018 | 352 | 0.470 |
Why?
| | Neovascularization, Pathologic | 2 | 2015 | 296 | 0.470 |
Why?
| | Fluorescent Dyes | 6 | 2021 | 324 | 0.470 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2015 | 77 | 0.460 |
Why?
| | Macrophages, Alveolar | 1 | 2018 | 396 | 0.450 |
Why?
| | Arthritis, Rheumatoid | 2 | 2025 | 1178 | 0.440 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 60 | 0.440 |
Why?
| | Ligands | 2 | 2014 | 667 | 0.440 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 195 | 0.430 |
Why?
| | Neutrophils | 1 | 2020 | 1282 | 0.430 |
Why?
| | Immunomagnetic Separation | 1 | 2013 | 4 | 0.400 |
Why?
| | Polymers | 1 | 2017 | 495 | 0.400 |
Why?
| | Carbocyanines | 2 | 2025 | 37 | 0.390 |
Why?
| | Tissue Distribution | 4 | 2017 | 330 | 0.390 |
Why?
| | Rats | 4 | 2025 | 5637 | 0.380 |
Why?
| | Complement C1q | 3 | 2022 | 38 | 0.380 |
Why?
| | Dogs | 2 | 2025 | 427 | 0.370 |
Why?
| | Epithelial Cell Adhesion Molecule | 4 | 2017 | 11 | 0.370 |
Why?
| | Receptors, Complement 3b | 2 | 2023 | 82 | 0.370 |
Why?
| | Mice, Inbred C57BL | 9 | 2021 | 5909 | 0.370 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1258 | 0.360 |
Why?
| | Female | 24 | 2025 | 75943 | 0.350 |
Why?
| | T-Lymphocytes | 3 | 2025 | 2007 | 0.340 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1474 | 0.310 |
Why?
| | Kallikrein-Kinin System | 1 | 2009 | 1 | 0.310 |
Why?
| | Breast Neoplasms | 2 | 2021 | 2257 | 0.300 |
Why?
| | Oxides | 1 | 2009 | 50 | 0.300 |
Why?
| | Flow Cytometry | 2 | 2025 | 1197 | 0.300 |
Why?
| | Arthritis, Experimental | 2 | 2020 | 141 | 0.280 |
Why?
| | Lymphoma, B-Cell | 1 | 2009 | 131 | 0.280 |
Why?
| | Cells, Cultured | 4 | 2023 | 4212 | 0.270 |
Why?
| | Neoplasms, Experimental | 2 | 2020 | 174 | 0.250 |
Why?
| | Iron | 1 | 2009 | 324 | 0.250 |
Why?
| | Biomimetics | 1 | 2007 | 43 | 0.250 |
Why?
| | Complement Factor H | 2 | 2025 | 79 | 0.250 |
Why?
| | Cholesterol | 2 | 2005 | 405 | 0.250 |
Why?
| | Male | 16 | 2025 | 70179 | 0.250 |
Why?
| | Cations | 3 | 2006 | 85 | 0.240 |
Why?
| | Drug Stability | 4 | 2017 | 166 | 0.220 |
Why?
| | Gentamicins | 1 | 2025 | 52 | 0.220 |
Why?
| | Synovial Membrane | 1 | 2025 | 121 | 0.210 |
Why?
| | Proteomics | 2 | 2021 | 1138 | 0.210 |
Why?
| | Complement Membrane Attack Complex | 1 | 2024 | 38 | 0.210 |
Why?
| | Complement C5 | 1 | 2024 | 80 | 0.210 |
Why?
| | Complement C5a | 1 | 2024 | 71 | 0.210 |
Why?
| | Complement C3a | 1 | 2024 | 42 | 0.210 |
Why?
| | Half-Life | 2 | 2014 | 146 | 0.210 |
Why?
| | Cell Adhesion Molecules | 3 | 2014 | 180 | 0.210 |
Why?
| | DNA, Recombinant | 1 | 2003 | 48 | 0.210 |
Why?
| | Immunoassay | 1 | 2024 | 113 | 0.200 |
Why?
| | Recombinant Fusion Proteins | 2 | 2023 | 674 | 0.200 |
Why?
| | Immunologic Memory | 1 | 2025 | 360 | 0.200 |
Why?
| | Polyamines | 3 | 2021 | 44 | 0.200 |
Why?
| | Middle Aged | 6 | 2025 | 34647 | 0.200 |
Why?
| | Ultrasonics | 2 | 2014 | 50 | 0.200 |
Why?
| | DNA | 3 | 2009 | 1444 | 0.200 |
Why?
| | Spermine | 2 | 2005 | 31 | 0.190 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 230 | 0.190 |
Why?
| | Urinary Tract Infections | 1 | 2025 | 194 | 0.190 |
Why?
| | Injections, Intravenous | 2 | 2017 | 202 | 0.180 |
Why?
| | Adult | 7 | 2025 | 39391 | 0.180 |
Why?
| | Biological Products | 1 | 2025 | 239 | 0.180 |
Why?
| | Microscopy, Fluorescence | 2 | 2021 | 418 | 0.180 |
Why?
| | Dendrimers | 1 | 2021 | 18 | 0.180 |
Why?
| | Rats, Long-Evans | 1 | 2021 | 122 | 0.170 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 703 | 0.170 |
Why?
| | Diffusion | 2 | 2019 | 121 | 0.170 |
Why?
| | Temperature | 2 | 2014 | 669 | 0.170 |
Why?
| | Single-Chain Antibodies | 1 | 2020 | 17 | 0.170 |
Why?
| | Synoviocytes | 1 | 2020 | 18 | 0.170 |
Why?
| | Kupffer Cells | 2 | 2012 | 49 | 0.160 |
Why?
| | Models, Molecular | 3 | 2013 | 1604 | 0.160 |
Why?
| | Microscopy, Confocal | 1 | 2021 | 324 | 0.160 |
Why?
| | HEK293 Cells | 2 | 2013 | 737 | 0.160 |
Why?
| | Hindlimb | 1 | 2020 | 134 | 0.160 |
Why?
| | Multimodal Imaging | 1 | 2020 | 120 | 0.160 |
Why?
| | Testis | 1 | 2020 | 158 | 0.160 |
Why?
| | Joints | 1 | 2020 | 106 | 0.160 |
Why?
| | Hematinics | 1 | 2019 | 21 | 0.160 |
Why?
| | Phospholipids | 1 | 2021 | 221 | 0.160 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2020 | 86 | 0.160 |
Why?
| | Heterocyclic Compounds, 1-Ring | 1 | 2019 | 6 | 0.150 |
Why?
| | Foot | 1 | 2020 | 100 | 0.150 |
Why?
| | Muscles | 1 | 2020 | 333 | 0.150 |
Why?
| | Complement C3-C5 Convertases | 1 | 2019 | 23 | 0.150 |
Why?
| | Fluorescein-5-isothiocyanate | 2 | 2009 | 38 | 0.150 |
Why?
| | Magnetics | 2 | 2009 | 48 | 0.150 |
Why?
| | Prostate | 1 | 2020 | 173 | 0.150 |
Why?
| | Jurkat Cells | 1 | 2019 | 138 | 0.150 |
Why?
| | Lectins | 1 | 2019 | 46 | 0.150 |
Why?
| | Color | 1 | 2019 | 82 | 0.150 |
Why?
| | Bone Marrow Cells | 1 | 2020 | 327 | 0.150 |
Why?
| | Molecular Structure | 2 | 2018 | 503 | 0.150 |
Why?
| | Opsins | 1 | 2018 | 10 | 0.140 |
Why?
| | Immunity, Innate | 3 | 2023 | 852 | 0.140 |
Why?
| | Femur | 1 | 2020 | 260 | 0.140 |
Why?
| | Endothelium, Vascular | 2 | 2023 | 951 | 0.140 |
Why?
| | Cell Movement | 1 | 2023 | 990 | 0.140 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 298 | 0.140 |
Why?
| | Equipment Design | 2 | 2017 | 525 | 0.140 |
Why?
| | Archaeal Viruses | 1 | 2017 | 12 | 0.140 |
Why?
| | Proteins | 2 | 2017 | 1015 | 0.140 |
Why?
| | Cartilage | 1 | 2019 | 192 | 0.140 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4421 | 0.130 |
Why?
| | Drug Liberation | 1 | 2017 | 36 | 0.130 |
Why?
| | MCF-7 Cells | 1 | 2017 | 126 | 0.130 |
Why?
| | Administration, Intravesical | 1 | 2017 | 15 | 0.130 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2025 | 907 | 0.130 |
Why?
| | Silicon Dioxide | 1 | 2018 | 118 | 0.130 |
Why?
| | Keratins | 1 | 2017 | 173 | 0.130 |
Why?
| | Camptothecin | 1 | 2017 | 123 | 0.130 |
Why?
| | Drug Compounding | 1 | 2017 | 104 | 0.130 |
Why?
| | Models, Animal | 1 | 2018 | 396 | 0.120 |
Why?
| | Optical Imaging | 1 | 2017 | 66 | 0.120 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2017 | 192 | 0.120 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 258 | 0.120 |
Why?
| | Inflammation | 2 | 2024 | 2902 | 0.120 |
Why?
| | Protein Conformation | 1 | 2019 | 941 | 0.120 |
Why?
| | Repressor Proteins | 1 | 2019 | 430 | 0.120 |
Why?
| | Swine | 1 | 2018 | 812 | 0.120 |
Why?
| | Sheep | 1 | 2018 | 874 | 0.120 |
Why?
| | Sodium Hydroxide | 1 | 2014 | 8 | 0.110 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 447 | 0.110 |
Why?
| | Complement Pathway, Classical | 1 | 2014 | 21 | 0.110 |
Why?
| | Cross-Linking Reagents | 1 | 2015 | 208 | 0.110 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2014 | 23 | 0.110 |
Why?
| | Endocytosis | 1 | 2015 | 175 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1866 | 0.110 |
Why?
| | Umbilical Veins | 1 | 2014 | 61 | 0.110 |
Why?
| | Antigen-Antibody Reactions | 1 | 2014 | 54 | 0.110 |
Why?
| | Penicillinase | 1 | 2014 | 1 | 0.110 |
Why?
| | Nanoshells | 1 | 2014 | 1 | 0.110 |
Why?
| | Bacillus cereus | 1 | 2014 | 5 | 0.110 |
Why?
| | Molecular Imaging | 1 | 2014 | 55 | 0.110 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2014 | 27 | 0.110 |
Why?
| | Kinetics | 1 | 2017 | 1655 | 0.110 |
Why?
| | Thrombosis | 2 | 2009 | 399 | 0.100 |
Why?
| | Staurosporine | 1 | 2013 | 20 | 0.100 |
Why?
| | Nanocapsules | 1 | 2013 | 14 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 420 | 0.100 |
Why?
| | Cells, Immobilized | 1 | 2013 | 21 | 0.100 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2013 | 33 | 0.100 |
Why?
| | Species Specificity | 1 | 2014 | 583 | 0.100 |
Why?
| | Models, Biological | 2 | 2019 | 1828 | 0.100 |
Why?
| | Blood Cells | 1 | 2013 | 39 | 0.100 |
Why?
| | Lung | 3 | 2018 | 4137 | 0.100 |
Why?
| | Gene Expression | 2 | 2012 | 1492 | 0.100 |
Why?
| | Molecular Conformation | 1 | 2013 | 147 | 0.100 |
Why?
| | Protein Kinase C | 1 | 2013 | 252 | 0.090 |
Why?
| | Kininogens | 1 | 2012 | 6 | 0.090 |
Why?
| | Iron-Dextran Complex | 1 | 2012 | 7 | 0.090 |
Why?
| | Mannose-Binding Lectins | 1 | 2012 | 11 | 0.090 |
Why?
| | Mannans | 1 | 2012 | 6 | 0.090 |
Why?
| | Blood Platelets | 1 | 2015 | 437 | 0.090 |
Why?
| | Lectins, C-Type | 1 | 2012 | 63 | 0.090 |
Why?
| | Pharmaceutical Vehicles | 1 | 2011 | 12 | 0.090 |
Why?
| | High-Energy Shock Waves | 1 | 2011 | 4 | 0.090 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 1485 | 0.090 |
Why?
| | Collagen Type I | 1 | 2012 | 140 | 0.090 |
Why?
| | Mice, Knockout | 2 | 2017 | 3071 | 0.090 |
Why?
| | Cloning, Molecular | 1 | 2012 | 533 | 0.090 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2011 | 107 | 0.080 |
Why?
| | Mice, Transgenic | 2 | 2007 | 2184 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 859 | 0.080 |
Why?
| | Receptors, Cell Surface | 1 | 2012 | 398 | 0.080 |
Why?
| | Models, Theoretical | 1 | 2013 | 584 | 0.080 |
Why?
| | Molecular Weight | 1 | 2009 | 329 | 0.070 |
Why?
| | Aged | 2 | 2025 | 24746 | 0.070 |
Why?
| | Nanostructures | 1 | 2009 | 114 | 0.070 |
Why?
| | Phosphatidylcholines | 2 | 2014 | 136 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2009 | 811 | 0.070 |
Why?
| | Bacterial Proteins | 1 | 2014 | 912 | 0.070 |
Why?
| | Plasma | 1 | 2009 | 221 | 0.070 |
Why?
| | Carcinoma | 1 | 2009 | 230 | 0.060 |
Why?
| | United States | 1 | 2024 | 15310 | 0.060 |
Why?
| | Cell Line | 1 | 2012 | 2887 | 0.060 |
Why?
| | CpG Islands | 1 | 2006 | 165 | 0.060 |
Why?
| | Interleukin-13 Receptor alpha2 Subunit | 1 | 2025 | 6 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5169 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3737 | 0.060 |
Why?
| | Iodine Radioisotopes | 1 | 2025 | 144 | 0.060 |
Why?
| | Serum Albumin | 1 | 2005 | 153 | 0.060 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2025 | 110 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2005 | 240 | 0.050 |
Why?
| | Rheumatoid Factor | 1 | 2025 | 177 | 0.050 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2005 | 176 | 0.050 |
Why?
| | Micelles | 1 | 2004 | 39 | 0.050 |
Why?
| | Heparin | 1 | 2005 | 259 | 0.050 |
Why?
| | Biological Transport, Active | 1 | 2003 | 71 | 0.050 |
Why?
| | Biomarkers | 1 | 2014 | 4190 | 0.050 |
Why?
| | Luciferases | 1 | 2003 | 150 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 2158 | 0.050 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 579 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 358 | 0.050 |
Why?
| | Mannose-Binding Lectin | 1 | 2021 | 21 | 0.040 |
Why?
| | Glycerophospholipids | 1 | 2001 | 36 | 0.040 |
Why?
| | Mannose-Binding Protein-Associated Serine Proteases | 1 | 2021 | 17 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2001 | 164 | 0.040 |
Why?
| | Circular Dichroism | 1 | 2001 | 148 | 0.040 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 5 | 0.040 |
Why?
| | Trastuzumab | 1 | 2021 | 97 | 0.040 |
Why?
| | Peptides | 1 | 2007 | 979 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 2001 | 441 | 0.040 |
Why?
| | Phagocytosis | 1 | 2023 | 389 | 0.040 |
Why?
| | Bacteriophage lambda | 1 | 2021 | 89 | 0.040 |
Why?
| | Thymocytes | 1 | 2020 | 35 | 0.040 |
Why?
| | Luminescent Proteins | 1 | 2001 | 181 | 0.040 |
Why?
| | Influenza Vaccines | 1 | 2005 | 551 | 0.040 |
Why?
| | Mice, Inbred DBA | 1 | 2020 | 200 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 96 | 0.040 |
Why?
| | Plasmids | 1 | 2001 | 365 | 0.040 |
Why?
| | Theranostic Nanomedicine | 1 | 2020 | 14 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 108 | 0.040 |
Why?
| | Microspheres | 1 | 2020 | 142 | 0.040 |
Why?
| | Green Fluorescent Proteins | 1 | 2001 | 401 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 310 | 0.040 |
Why?
| | Nanotechnology | 1 | 2020 | 124 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2001 | 401 | 0.040 |
Why?
| | Apoptosis | 2 | 2020 | 2576 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 178 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 161 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2001 | 528 | 0.030 |
Why?
| | Extremophiles | 1 | 2017 | 2 | 0.030 |
Why?
| | Immunity | 1 | 2018 | 140 | 0.030 |
Why?
| | Sulfolobus | 1 | 2017 | 11 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2025 | 2828 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2017 | 157 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6966 | 0.030 |
Why?
| | Lecithins | 1 | 2014 | 5 | 0.030 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 266 | 0.020 |
Why?
| | Mice, Nude | 1 | 2013 | 691 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 368 | 0.020 |
Why?
| | Phantoms, Imaging | 1 | 2012 | 150 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 1134 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2765 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1158 | 0.020 |
Why?
| | Materials Testing | 1 | 2009 | 354 | 0.020 |
Why?
| | Salmon | 1 | 2006 | 21 | 0.020 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 149 | 0.020 |
Why?
| | Nasal Lavage Fluid | 1 | 2005 | 15 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2005 | 31 | 0.020 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2006 | 143 | 0.020 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2005 | 38 | 0.020 |
Why?
| | Polyelectrolytes | 1 | 2005 | 15 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2005 | 92 | 0.010 |
Why?
| | Spermatozoa | 1 | 2006 | 96 | 0.010 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2005 | 46 | 0.010 |
Why?
| | Gene Transfer Techniques | 1 | 2006 | 176 | 0.010 |
Why?
| | Ceramides | 1 | 2005 | 117 | 0.010 |
Why?
| | Immunity, Mucosal | 1 | 2005 | 96 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1094 | 0.010 |
Why?
| | Rabbits | 1 | 2005 | 754 | 0.010 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2005 | 151 | 0.010 |
Why?
| | Genetic Therapy | 1 | 2006 | 315 | 0.010 |
Why?
| | Spleen | 1 | 2005 | 525 | 0.010 |
Why?
| | Cattle | 1 | 2006 | 998 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2006 | 676 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 650 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2005 | 656 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 11181 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2005 | 2506 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2100 | 0.010 |
Why?
|
|
Simberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|